|
JPH0487425A
(ja)
*
|
1990-07-31 |
1992-03-19 |
Fujitsu Ltd |
回線切り替え装置
|
|
ES2296979T3
(es)
|
2001-06-27 |
2008-05-01 |
Smithkline Beecham Corporation |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
|
|
US7420079B2
(en)
*
|
2002-12-09 |
2008-09-02 |
Bristol-Myers Squibb Company |
Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
|
|
US7550590B2
(en)
|
2003-03-25 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
WO2004103993A1
(en)
|
2003-05-14 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
|
DK1715893T3
(da)
|
2004-01-20 |
2009-11-09 |
Novartis Pharma Ag |
Direkte kompressionsformulering og fremgangsmåde
|
|
TW200538122A
(en)
|
2004-03-31 |
2005-12-01 |
Bristol Myers Squibb Co |
Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
|
|
US7741082B2
(en)
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
|
TW200536827A
(en)
|
2004-05-04 |
2005-11-16 |
Bristol Myers Squibb Co |
Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
|
|
US7214702B2
(en)
*
|
2004-05-25 |
2007-05-08 |
Bristol-Myers Squibb Company |
Process for producing a dipeptidyl peptidase IV inhibitor
|
|
DE102004035978A1
(de)
*
|
2004-07-23 |
2006-03-16 |
Justus-Liebig-Universität Giessen |
Aminoadamantan-Verbindungen
|
|
US20060035954A1
(en)
*
|
2004-08-11 |
2006-02-16 |
Sharma Padam N |
Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
|
|
EP1789376A1
(en)
|
2004-09-17 |
2007-05-30 |
Albemarle Corporation |
Synthesis process for 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
WO2006107963A2
(en)
*
|
2005-04-06 |
2006-10-12 |
Novartis Ag |
Process for preparing dipeptide amides
|
|
FI120765B
(fi)
*
|
2005-05-31 |
2010-02-26 |
Kemfine Group Ltd |
Menetelmä adamantaanijohdannaisten valmistamiseksi
|
|
US7205432B2
(en)
*
|
2005-05-31 |
2007-04-17 |
Kemfine Oy |
Process for the preparation of adamantane derivatives
|
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
|
GEP20135838B
(en)
|
2005-09-14 |
2013-06-10 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors usage at diabetes treatment
|
|
CN101360723A
(zh)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
AU2007235876A1
(en)
|
2006-04-12 |
2007-10-18 |
Probiodrug Ag |
Enzyme inhibitors
|
|
JP5272324B2
(ja)
*
|
2006-04-17 |
2013-08-28 |
住友化学株式会社 |
Ｎ−ｔｅｒｔ−ブトキシカルボニル−２−ピロリジノン類およびその製造方法
|
|
CN101415676A
(zh)
*
|
2006-04-17 |
2009-04-22 |
住友化学株式会社 |
N-叔丁氧基羰基-2-吡咯烷酮类及其制造方法
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
EP2089383B1
(en)
|
2006-11-09 |
2015-09-16 |
Probiodrug AG |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
CN101687844B
(zh)
|
2007-07-02 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
用作ccr2受体拮抗剂的咪唑衍生物
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
US8338450B2
(en)
*
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
UA119131C2
(uk)
|
2008-08-15 |
2019-05-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань
|
|
JP2012509277A
(ja)
*
|
2008-11-19 |
2012-04-19 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
ジペプチジルペプチダーゼｉｖのヒドロキシアダマンチル阻害剤
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
|
EP2395988A2
(en)
|
2009-02-13 |
2011-12-21 |
Boehringer Ingelheim International GmbH |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
BRPI1008560B1
(pt)
|
2009-02-13 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
|
|
SG174504A1
(en)
|
2009-03-27 |
2011-10-28 |
Bristol Myers Squibb Co |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
US8158394B2
(en)
*
|
2009-04-08 |
2012-04-17 |
Bristol-Myers Squibb Company |
Genetically stable plasmid expressing PDH and FDH enzymes
|
|
AU2010233718B2
(en)
*
|
2009-04-09 |
2015-11-05 |
Sandoz Ag |
Crystal forms of Saxagliptin
|
|
US8748457B2
(en)
|
2009-06-18 |
2014-06-10 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
|
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
|
JP5934645B2
(ja)
|
2009-09-11 |
2016-06-15 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
|
|
US20110269956A1
(en)
*
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
FR2956400A1
(fr)
|
2010-02-15 |
2011-08-19 |
Finorga |
Procede de preparation de composes adamantyles
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
|
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
|
|
EP2368874A1
(en)
|
2010-03-26 |
2011-09-28 |
Sandoz AG |
Racemisation of (R)-N-Boc-3-hydroxyadamant-1-yl glycine
|
|
AU2011237775A1
(en)
|
2010-04-06 |
2012-11-22 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
|
US8501960B2
(en)
|
2010-05-05 |
2013-08-06 |
Assia Chemical Industries Ltd. |
Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
|
|
CA3070513C
(en)
|
2010-05-05 |
2023-01-03 |
Boehringer Ingelheim International Gmbh |
A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
|
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
CN103370064A
(zh)
|
2010-09-03 |
2013-10-23 |
百时美施贵宝公司 |
使用水溶性抗氧化剂的药物制剂
|
|
WO2012028721A1
(en)
|
2010-09-03 |
2012-03-08 |
Sandoz Ag |
PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
CN103249730A
(zh)
|
2010-09-24 |
2013-08-14 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
|
EP2608788A1
(en)
|
2010-10-04 |
2013-07-03 |
Assia Chemical Industries Ltd. |
Polymorphs of saxagliptin hydrochloride and processes for preparing them
|
|
CA2826391C
(en)
|
2011-02-01 |
2017-01-24 |
Bristol-Myers Squibb Company |
Pharmaceutical formulations including an amine compound
|
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
EP2713730A4
(en)
|
2011-05-24 |
2015-08-05 |
Apicore Llc |
PROCESS FOR THE PRODUCTION OF SAXAGLIPTIN AND NEW INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
JPWO2013081100A1
(ja)
*
|
2011-11-30 |
2015-04-27 |
積水メディカル株式会社 |
アダマンチルヒダントイン化合物
|
|
ITMI20120842A1
(it)
*
|
2012-05-16 |
2013-11-17 |
Chemelectiva S R L |
Intermedi utili per la preparazione di saxagliptina e processo per la loro preparazione
|
|
WO2013175395A2
(en)
*
|
2012-05-21 |
2013-11-28 |
Dr. Reddys Laboratories Limited |
Improved process for preparation of saxagliptin and its salts
|
|
US8664443B2
(en)
|
2012-05-23 |
2014-03-04 |
Divi's Laboratories Ltd. |
Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
US9994523B2
(en)
|
2012-05-24 |
2018-06-12 |
Apotex Inc. |
Salts of Saxagliptin with organic acids
|
|
AU2013285078A1
(en)
|
2012-07-02 |
2015-01-29 |
Sun Pharmaceutical Industries Limited |
Saxagliptin salts
|
|
CN103539724B
(zh)
*
|
2012-07-12 |
2017-09-26 |
博瑞生物医药（苏州）股份有限公司 |
沙格列汀单一立体异构体的新晶型和纯化方法
|
|
WO2014057495A1
(en)
|
2012-10-11 |
2014-04-17 |
Lee Pharma Limited |
A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
WO2014108830A1
(en)
|
2013-01-10 |
2014-07-17 |
Wockhardt Limited |
A process for preparing pharmaceutically acceptable salt of saxagliptin
|
|
CN104098481B
(zh)
*
|
2013-04-10 |
2016-05-11 |
浙江九洲药物科技有限公司 |
一种沙格列汀中间体的制备方法
|
|
CN103265473A
(zh)
*
|
2013-06-04 |
2013-08-28 |
上海同昌生物医药科技有限公司 |
一种生产沙格列汀的方法
|
|
CN104370769B
(zh)
*
|
2013-08-14 |
2017-05-31 |
重庆博腾制药科技股份有限公司 |
一种制备羟基金刚烷甘氨酸衍生物的方法
|
|
WO2015031595A1
(en)
*
|
2013-08-28 |
2015-03-05 |
Amneal Pharmaceuticals Llc |
A process for preparation of saxagliptin and its hydrochloride salt
|
|
CN103450071A
(zh)
*
|
2013-09-05 |
2013-12-18 |
南京工业大学 |
一种医药中间体2-氮杂双环[3.1.0]己烷-2,3-二碳酸叔丁酯的不对称合成方法
|
|
CN103435533A
(zh)
*
|
2013-09-09 |
2013-12-11 |
嘉兴学院 |
具有环丙烷结构的s-脯氨醇手性有机小分子化合物及其合成方法
|
|
CN103435534A
(zh)
*
|
2013-09-09 |
2013-12-11 |
嘉兴学院 |
具有环丙烷结构s-脯氨酸的制备方法
|
|
CN103467361A
(zh)
*
|
2013-09-09 |
2013-12-25 |
嘉兴学院 |
具有环丙烷结构s-脯氨酸的吗啉衍生物及其制备方法
|
|
CN103467360A
(zh)
*
|
2013-09-09 |
2013-12-25 |
嘉兴学院 |
具有环丙烷结构r-脯氨酸的吗啉衍生物及其制备方法
|
|
CN103435536A
(zh)
*
|
2013-09-09 |
2013-12-11 |
嘉兴学院 |
具有环丙烷结构s-脯氨酸的吡咯衍生物及其制备方法
|
|
CN103435535A
(zh)
*
|
2013-09-09 |
2013-12-11 |
嘉兴学院 |
具有环丙烷结构r-脯氨酸的制备方法
|
|
CN103450074A
(zh)
*
|
2013-09-09 |
2013-12-18 |
嘉兴学院 |
具有环丙烷结构的r-脯氨醇手性有机小分子化合物及其合成方法
|
|
CN103467362A
(zh)
*
|
2013-09-09 |
2013-12-25 |
嘉兴学院 |
具有环丙烷结构s-二苯基脯氨醇类手性有机小分子化合物及其合成方法
|
|
CN103450073A
(zh)
*
|
2013-09-09 |
2013-12-18 |
嘉兴学院 |
具有环丙烷结构r-二苯基脯氨醇类手性有机小分子化合物及其合成方法
|
|
CN104649953A
(zh)
*
|
2013-11-25 |
2015-05-27 |
天津市汉康医药生物技术有限公司 |
一种沙格列汀倍半水合物化合物
|
|
WO2015087262A1
(en)
|
2013-12-11 |
2015-06-18 |
Ranbaxy Laboratories Limited |
Process for the preparation of saxagliptin and its intermediates
|
|
CN104829444A
(zh)
*
|
2014-02-12 |
2015-08-12 |
上海医药工业研究院 |
一种α-溴代三环[3.3.1.13,7]癸烷-1-乙酸的后处理方法
|
|
CN103910669B
(zh)
*
|
2014-04-04 |
2015-10-21 |
苏州景泓生物技术有限公司 |
沙格列汀关键中间体的制备方法
|
|
CN103951588B
(zh)
*
|
2014-04-30 |
2016-10-05 |
淮海工学院 |
一种合成沙格列汀中间体n-叔丁氧羰基-3-羟基-1-金刚烷基-d-甘氨酸的方法
|
|
CN105315189A
(zh)
*
|
2014-05-29 |
2016-02-10 |
上海医药工业研究院 |
一种制备（5s）-5-氨基羰基-4,5-二氢-1h-吡咯-1-羧酸-1（1,1-二甲基乙基）酯的方法
|
|
CN104109100A
(zh)
*
|
2014-05-29 |
2014-10-22 |
上海应用技术学院 |
一种金刚烷氨基酸酯化合物的合成方法
|
|
CN104098505A
(zh)
*
|
2014-07-31 |
2014-10-15 |
天津民祥生物医药科技有限公司 |
一种沙格列汀的制备方法
|
|
CN104098487A
(zh)
*
|
2014-07-31 |
2014-10-15 |
天津民祥生物医药科技有限公司 |
一种n-叔丁氧羰基-3-羟基-1-金刚烷基甘氨酸的制备方法
|
|
WO2016026827A1
(en)
*
|
2014-08-20 |
2016-02-25 |
Sandoz Ag |
Crystalline boc-s-hadgly and process for its preparation
|
|
CN104293844B
(zh)
*
|
2014-08-26 |
2017-10-10 |
苏州永健生物医药有限公司 |
一种特拉匹韦中间体的合成方法
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
CN105503698A
(zh)
*
|
2014-09-26 |
2016-04-20 |
深圳翰宇药业股份有限公司 |
一种合成沙格列汀及其中间体的方法
|
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
|
CN104817476B
(zh)
*
|
2015-03-25 |
2020-09-11 |
重庆医科大学 |
一种制备非天然氨基酸的方法
|
|
CN105037245B
(zh)
*
|
2015-08-03 |
2017-04-12 |
沧州那瑞化学科技有限公司 |
一种沙格列汀中间体的制备方法
|
|
CN105112469B
(zh)
*
|
2015-09-24 |
2018-07-27 |
福建省微生物研究所 |
酶催化不对称转氨基反应制备沙格列汀手性中间体的方法
|
|
CN106554301B
(zh)
*
|
2015-09-30 |
2018-09-21 |
深圳翰宇药业股份有限公司 |
一种沙格列汀关键中间体的制备方法
|
|
KR101715682B1
(ko)
|
2015-10-29 |
2017-03-13 |
경동제약 주식회사 |
삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법
|
|
DE102016116130A1
(de)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Verfahren zur Herstellung chiraler Aminonitrile
|
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
|
WO2019241574A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for lowering blood sugar with a dipeptidyl peptidase-4 inhibitor pharmaceutical composition
|
|
EP3914605B2
(en)
*
|
2019-01-24 |
2026-04-29 |
DSM IP Assets B.V. |
Peptide precipitation method
|
|
CN111170927B
(zh)
*
|
2020-04-10 |
2020-08-04 |
上海翰森生物医药科技有限公司 |
一种沙格列汀中间体的制备方法
|
|
CN112391363B
(zh)
*
|
2021-01-21 |
2021-04-06 |
凯莱英生命科学技术(天津)有限公司 |
氨基酸脱氢酶突变体及其应用
|
|
CN114621068A
(zh)
*
|
2022-03-31 |
2022-06-14 |
沧州那瑞化学科技有限公司 |
3-羟基-1-金刚烷甲基酮的制备方法及合成沙格列汀的方法
|